Browsing Tag
Biopharmaceuticals
13 posts
Dizal’s sunvozertinib beats chemo in phase 3 first-line NSCLC trial, opening path to new drug applications
Dizal's sunvozertinib beats platinum chemo in WU-KONG28 phase 3 first-line EGFR exon 20 NSCLC trial. What this means for patients, rivals and investors. Read more.
Can Ascendis Pharma’s TransCon CNP still win FDA approval after the review extension?
FDA delays decision on Ascendis Pharma’s dwarfism drug TransCon CNP to February 2026 due to protocol revisions. See how this affects approval odds and launch.
Why is Novartis acquiring Tourmaline Bio—and how does pacibekitug fit into its cardiovascular pipeline?
Novartis is acquiring Tourmaline Bio in a $1.4B deal to advance pacibekitug, a promising anti-IL-6 therapy for atherosclerotic cardiovascular disease.
Sun Pharmaceutical faces regulatory pause as EMA application for melanoma drug withdrawn
Sun Pharmaceutical’s EU partner Philogen has withdrawn its EMA application for Nidlegy, delaying regulatory progress in melanoma care. Read what’s next.
Biocon Biologics strengthens US market presence with Civica insulin deal
As insulin prices remain a pressing concern in the United States, Biocon Biologics collaboration with Civica, Inc. has…
Praxis Precision Medicines faces major setback in ulixacaltamide trial but remains committed to Essential3 study
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company specializing in treatments for central nervous system disorders, encountered…
UCB to divest mature neurology and allergy portfolio in China for $680m to CBC Group and Mubadala
UCB, a Belgian biopharmaceutical company, has announced the divestment of its mature neurology and allergy portfolio in China…
Shockwave through biotech: AN2 Therapeutics slashes workforce after trial fails
AN2 Therapeutics, Inc., a pioneering force in novel small molecule drugs, has announced a dramatic reduction of its…
Antengene’s XPOVIO approved in China for diffuse large B-cell lymphoma
Antengene Corporation Limited, a commercial-stage global biopharmaceutical company, has announced a significant milestone with the China National Medical…
CASI Pharmaceuticals advances in kidney transplant treatment and explores strategic sale in China
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a notable player in the biopharmaceutical sector, has made a significant announcement that…